Why is Marksans Pharma falling/rising?

As of 11-Aug, Marksans Pharma Ltd is currently priced at 211.00, reflecting a decrease of 0.15 (-0.07%). The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 6.68% over the past week and 17.12% over the past month. Additionally, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The delivery volume has also decreased significantly, falling by 27.9% compared to the 5-day average, suggesting a decline in investor participation. While the company boasts high management efficiency with a return on equity (ROE) of 17.66% and low debt levels, the long-term growth prospects appear poor, with operating profit growth averaging only 2.87% over the last five years.
In the broader market context, Marksans Pharma's performance has been notably weaker than the benchmark, with a 1-week decline of 6.68% compared to the Sensex's modest drop of 0.51%. Despite generating a positive return of 7.71% over the past year, the stock's profitability has not kept pace with its valuation, as indicated by a high price-to-book ratio of 3.9. This disparity, along with flat results in recent quarters and a low inventory turnover ratio, raises concerns among investors, contributing to the stock's downward movement. Overall, while institutional holdings are relatively high at 25.38%, the combination of poor growth metrics and declining investor interest has led to the stock's recent struggles.